PDE5 inhibitors for cystic fibrosis: Can they also enhance chloride transport?

Expert Opinion on Investigational Drugs

Volumn 17, Issue 6, 2008, Pages 965-968

  Antoniu, Sabina A ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Animal models; Cystic fibronis; Sildenafil; Vardenafil

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TRANSMEMBRANE CONDUCTANCE REGULATOR; VARDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHLORIDE CONDUCTANCE; CHLORIDE TRANSPORT; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG MECHANISM; MOUSE; NONHUMAN; SINGLE DRUG DOSE; SODIUM CONDUCTANCE; WILD TYPE;

EID: 45749128219     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.6.965     Document Type: Article

References (9)

1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352(19):1992-2001
2. Galietta L. Cystic fibrosis transmembrane conductance regulator pharmacotherapy. In: Larsson K, editor, Cystic fibrosis. European Respiratory Monograph; 2006. p. 88-104
3. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004;23(1):146-58
4. Lubamba B, Lecourt H, Lebacq J, et al. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med 2008;177(5):506-15
5. Kelley TJ, Al-Nakkash L, Drumm ML. CFTR-mediated chloride permeability is regulated by type III phosphodiesterases in airway epithelial cells. Am J Respir Cell Mol Biol 1995;13(6):657-64
6. Kelley TJ, Al-Nakkash L, Cotton CU, Drumm ML. Activation of endogenous deltaF508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition. J Clin Invest 1996;98(2):513-20
7. Al-Nakkash L, Hwang TC. Activation of wild-type and deltaF508-CFTR by phosphodiesterase inhibitors through cAMP-dependent and -independent mechanisms. Pflugers Arch 1999;437(4):553-61
8. Dormer RL, Harris CM, Clark Z, et al. Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax 2005;60(1):55-9
9. Poschet JF, Timinins GS, Taylor-Cousar JL, et al. Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment. of respiratory pathology in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2007;293(3):L712-9